Institute for Cancer Research

Kjetil Taskén
Institute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

See introductory video with welcome to the ICR 

See full video covering all of ICR and its Departments 

Publication overview

Annual reports

 

Current news and events

Anita Sveen invited speaker at AACR special conference on colorectal cancer

Anita Sveen
Anita Sveen

Anita Sveen, project group leader and member of the Lothe lab at the Department of Molecular Oncology at the Institute for Cancer research, was invited speaker at the AACR special conference colorectal cancer, held October 1-4th in Portland, Oregon, USA.
In her well received speech Dr. Sveen presented the multidisciplinary work from the TEAM-ACT (Tumor Evolution in Advanced Models to Accelerate precision Cancer Therapy) - a strategic research area of OUS. 

Public Talk & Guest Lecture with Professor Ewan Birney:Genomic Medicine across the world; challenges, progress, opportunities and patient impact

Ewan Birney (Photo credit: Jeff Dowling/EMBL-EBI)
Ewan Birney (Photo credit: Jeff Dowling/EMBL-EBI)

Professor Ewan Birney, CBE FRS FMedSci, Deputy Director General, EMBL & Director, EMBL-EBI
European Bioinformatics Institute, EMBL, Cambridge, UK

When: Wednesday, October 19, 1200-1245 + Q&A
Where: Auditorium, Institute for Cancer Research, ground floor, Research Building (K building), Oslo University Hospital - Radium Hospital site

New Centre of Excellence:The PRecision Immunotherapy Alliance (PRIMA) funded with 155 mNOK

Co-directors Johanne Olweus and Karl Johan Malmberg
Co-directors Johanne Olweus and Karl Johan Malmberg

On September 23rd he Research Council of Norway published the results of the latest Centre of Excellence call.
The PRecision Immunotherapy Alliance (PRIMA) was funded as a CoE with 155 mNOK over 10 years.

The center will have Kalle Malmberg and Johanna Olweus as co-directors and includes their groups and that of June Myklebust (PI) at ICR, and also Ludvig Munthe, Jan Terje Andersen and Fridtjof Lund-Johansen at Department of Immunology and Transfusion Medicine (RH) as well as Emma Haapaniemi (NCMM) as PIs and with UiO as host and OUH as partner.

Article in "Cancers" receiving international attention:Fighting tumors through sugar deprivation

OUS co-authors, from left: Grigalavicius, Ezzatpanah, Raabe and Theodossiou.
OUS co-authors, from left: Grigalavicius, Ezzatpanah, Raabe and Theodossiou.

Scientists in the Protonics Group at the Institute of Cancer Research, together with colleagues from NCSR Demokritos, Athens, Greece, have found that apart from being a photosensitive drug, 5-ALA is also a potent inhibitor of the glycolytic enzyme lactate dehydrogenase (LDH).

Dr. Theodossis Theodossiou, leader of the research team, said, "We are delighted to have uncovered this alternative property of 5-ALA. The fact that 5-ALA is approved for the detection of malignant gliomas and GBM makes our findings more valuable and easier to apply in the clinic. "

School of Health Innovation arrange course for professors and managers:How to increase innovation in your lab

Assistant, associate and full professors, group leaders, clinicians, research coordinators from any public university or hospital from Norway, Sweden and Denmark are invited to sign up for a course on how to increase innovation in your lab and bridge the gap between scientist and health innovator in Trondheim 23–24 November.

The course is arranged by the School of Health Innovation, which was established by the University of Oslo, and aims to provide healthcare and life science researchers with tools and insight into how research can be put to use for the benefit of patients, the healthcare system and our society.

 

Units and subpages

View all subunitsHide all subunits